₹ 40.92
NAV (Apr 29)
Contrary to common perception, this category is also characterised by higher volatility.Investing in these funds will require investors to have a unique insight into the specific areas of investment that these funds focus on.In addition the investor will need to have the ability,inclination and expertise to monitor the prospects closely.Investors are therefore better off investing in diversified funds rather than this category.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Expense Ratio | 0.64 % |
Launched 6Y ago | 2018-11-30 |
AUM in Crores | 3018.8 |
ISIN | INF740KA1LG1 |
Lock-in (days) | No Lock-in |
Benchmark | BSE Healthcare Total Return Index |
SIP Minimum | 1000 |
Lumpsum Min. | 5000 |
Standard Deviation (3yr) | - |
Standard Deviation | 15.9 |
Beta | 0.9 |
Sharpe Ratio | 0.9 |
YTM | - |
Sun Pharmaceutical Industries Ltd.
11.7%Suven Pharmaceuticals Ltd.
10.47%Cipla Ltd.
7.77%Ipca Laboratories Ltd.
7.61%Lupin Ltd.
7.58%Healthcare
96.21%Insurance
1.38%Fund Name | Fund Size | |
---|---|---|
₹ 49,131 cr | ||
₹ 93,440 cr | ||
₹ 64,962 cr | ||
₹ 27,730 cr | ||
₹ 16,217 cr |